Polpril Nebi secured positive Polish reimbursement advice after bioequivalence and budget review. https://www.mattheneus.com/editorial/aotmit-polpril-nebi-final-positive-advice-budget-savings-2026-10-01 #HTA #Pharma #RegulatoryAffairs

A 66-per-QALY result is compelling only when the model's internal consistency holds up. https://www.mattheneus.com/editorial/pregnancy-measles-screening-cost-effectiveness-model-consistency-2026-10-01 #HTA #HealthEconomics #RWE

A 119-trial Bayesian network can separate supplement signals from ranking certainty, when uncertainty stays visible. https://www.mattheneus.com/editorial/pubmed-dietary-supplements-lower-limb-power-bayesian-network-meta-analysis-2026-10-01 #HTA #NMA #EvidenceSynthesis

PBAC recommends Palynziq for phenylketonuria after revised pricing, showing how financial arrangements can unlock access. https://www.mattheneus.com/editorial/pbac-palynziq-final-outcome-financial-arrangement-2026-07 #HTA #Pharma #HealthEconomics

A 13-trial review maps early analgesia options in acute pancreatitis, highlighting evidence to support treatment decisions. https://www.mattheneus.com/editorial/pubmed-acute-pancreatitis-early-analgesia-randomised-trials-2026-10-01 #HTA #EvidenceSynthesis #HealthEconomics

Europe’s life-sciences strategy needs an evidence commitment register to turn policy promises into accountable action. https://www.mattheneus.com/editorial/eu-life-sciences-policy-state-register-evidence-commitments-2026-10-05 #HTA #RegulatoryAffairs #EvidenceSynthesis

European regulators back Frehemgo for haemophilia A bleeding prophylaxis. #HTA #RegulatoryAffairs #Pharma https://www.mattheneus.com/editorial/ema-frehemgo-denecimig-haemophilia-a-positive-opinion-fviii-mimetic-2026-09-17

Australia aligns Fabry disease enzyme therapies under one PBS reimbursement pathway. #HTA #HealthEconomics #Pharma https://www.mattheneus.com/editorial/pbac-agalsidase-alfa-beta-fabry-pbs-switching-framework-2026-07

Heart failure affects 56 million people worldwide, but budget impact depends on the local etiologic mix. https://www.mattheneus.com/editorial/global-heart-failure-burden-local-budget-impact-denominator-2026-09-30 #HTA #HealthEconomics #RWE

Thailand's access threshold for luspatercept points to a required 90.5% price reduction. #HTA #HealthEconomics #Pharma https://www.mattheneus.com/editorial/thailand-luspatercept-price-threshold-budget-impact-2026-09-28

France gives durvalumab a minor added-benefit rating in resectable gastric cancer.

https://www.mattheneus.com/editorial/has-imfinzi-durvalumab-resectable-gastric-gej-matterhorn-asmr-iv-2026-09-11

#HTA #EvidenceSynthesis #Pharma

Australia’s PBAC backs subcutaneous amivantamab at IV price parity, highlighting the HTA role of formulation bridging.

https://www.mattheneus.com/editorial/pbac-amivantamab-subcutaneous-exon20-lung-cancer-formulation-bridge-2026-07

#HTA #Pharma #HealthEconomics

Korea's 100-day listing pathway puts post-launch evidence planning at the centre of durable value decisions. https://www.mattheneus.com/editorial/korea-100-day-listing-post-launch-value-evidence-plan-2026-10-04 #HTA #RWE #HealthEconomics

Germany’s final assessment finds elinzanetant’s added benefit unproven for menopause symptoms. https://www.mattheneus.com/editorial/g-ba-elinzanetant-menopause-final-resolution-oasis3-2026-10-01 #HTA #RegulatoryAffairs #Pharma

A Dutch reimbursement verdict turns on a price cut above 53% and a MAIC-based evidence case. https://www.mattheneus.com/editorial/zin-enhertu-her2-mutated-nsclc-price-cut-maic-2026-09-22 #HTA #MAIC #HealthEconomics #Pharma

Poland questions stand-alone nurse-led chronic wound care in its current design.

https://www.mattheneus.com/editorial/aotmit-nurse-led-chronic-wound-service-coverage-position-2026-09-28

#HTA #EvidenceSynthesis #HealthEconomics

Long-term follow-up strengthens the value case for outpatient labour induction.

https://www.mattheneus.com/editorial/outpatient-labour-induction-long-term-outcomes-cost-effectiveness-2026-10-03

#HTA #HealthEconomics #RWE

Specialised formula access expands for pyridoxine-dependent epilepsy.

https://www.mattheneus.com/editorial/pbac-ga1-anamix-pyridoxine-dependent-epilepsy-restricted-benefit-2026-07

#HTA #EvidenceSynthesis #HealthEconomics

AOTMiT recommends against Akeega reimbursement in metastatic prostate cancer, citing comparator uncertainty. https://www.mattheneus.com/editorial/aotmit-akeega-mhspc-negative-reimbursement-amplitude-comparator-uncertainty-2026-09-29 #HTA #HealthEconomics

France grants early access to first-line Braftovi in metastatic colorectal cancer, focusing attention on evidence for access decisions. https://www.mattheneus.com/editorial/has-braftovi-first-line-metastatic-colorectal-early-access-breakwater-2026-09-23 #HTA #Pharma